关于控股股东非公开发行可交换公司债券拟办理 部分股份担保及信托登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司(简称"公司"或"本公司"）于近日接到控股 股东北京和谐恒源科技有限公司（简称"和谐恒源"）的告知函，和谐恒源拟以 其持有的部分本公司股票为标的面向专业投资者非公开发行可交换公司债券（第 一期）并已取得深圳证券交易所（简称"深交所"）出具的《关于北京和谐恒源 科技有限公司非公开发行可交换公司债券符合深交所挂牌条件的无异议函》（深 证函〔2025〕730号）。和谐恒源拟发行期限为不超过3年（含），募集资金规模 不超过人民币6亿元（含）的可交换公司债券。本期债券分为二个品种，债券名 称分别为北京和谐恒源科技有限公司2025年面向专业投资者非公开发行可交换 公司债券（第一期）（品种一）、北京和谐恒源科技有限公司2025年面向专业投 资者非公开发行可交换公司债券（第一期）（品种二），其中品种一发行规模不 超过4亿元（含），品种二发行规模不超过2亿元（含）。 证券代码：000935 证券简称：四川双马 公告编号：2025-36 ...

Core Viewpoint - Sichuan Shuangma is actively involved in the pharmaceutical sector through direct investments and participation in funds, focusing on biopharmaceuticals and innovative technologies [1] Group 1: Direct Investments - The company’s direct investment primarily targets biopharmaceutical research and production enterprises, specifically Shenzhen Jianyuan, which specializes in the development and production of peptide raw materials and contract development and manufacturing (CDMO) [1] - Shenzhen Jianyuan also engages in the research and production of beauty peptides, indicating a diverse product range within the biopharmaceutical sector [1] Group 2: Fund Participation - Sichuan Shuangma participates in the Shanghai Hexie Huizi Fund, which adopts a venture capital strategy aimed at investing in cutting-edge technology innovation companies, particularly in new drug development and biotechnology [1] - The focus on biopharmaceutical funds highlights the company's commitment to advancing in the pharmaceutical industry through strategic investments [1]

Group 1 - The core point of the article is the strategic cooperation between Hanyu Pharmaceutical and the digital asset platform KuCoin to explore the tokenization of "future revenue rights of innovative drug research and development" as a pilot project in Hong Kong [1] - The company is actively exploring innovative models based on its operational needs and appreciates suggestions regarding potential collaborations with major shareholders and other digital asset platforms [1]

Group 1 - The stock price of Sichuan Shuangma closed at 19.33 yuan on August 4, 2025, with a slight decrease of 0.02 yuan, representing a drop of 0.10% [1] - The company reported a trading volume of 1.58 billion yuan, with a fluctuation of 1.91% and a turnover rate of 1.08% on the same day [1] - Sichuan Shuangma's main business includes cement and building materials, while also venturing into biotechnology and medical aesthetics [1] Group 2 - The company aims to continuously promote the development of its core business and focus on high-growth industries such as biotechnology [1] - Sichuan Shuangma is seeking synergistic business opportunities to enhance its long-term competitiveness [1] - In investor interactions, the company expressed its commitment to optimizing its business layout and enhancing investor confidence through performance growth and development prospects [1] Group 3 - On August 4, the net inflow of main funds was 3.6693 million yuan, with a cumulative net inflow of 22.8371 million yuan over the past five days [1]

证券之星消息，8月1日多元金融板块较上一交易日下跌0.02%，南华期货领跌。当日上证指数报收于 3559.95，下跌0.37%。深证成指报收于10991.32，下跌0.17%。多元金融板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600830 | 普流融通 | 11.47 | 6.01% | 54.37万 | 6.21亿 | | 600053 | 九鼎投资 | 16.31 | 2.00% | 9.26万 | 1.50亿 | | 000617 | 中油资本 | 8.77 | 1.27% | 299.70万 | 26.42 亿 | | 000532 | 华金资本 | 15.33 | 0.92% | 8.37万 | 1.28亿 | | 600318 | 新力金融 | 9.84 | 0.72% | 24.09万 | 2.37亿 | | 600120 | 浙江东方 | 6.08 | 0.66% | 41.97万 | 2.54亿 | | 000987 | 越秀资本 | 7.39 | ...

Core Viewpoint - Sichuan Shuangma's stock price experienced a decline of 1.82% on July 30, closing at 19.44 yuan, with a trading volume of 136,800 hands and a transaction amount of 266 million yuan [1][2]. Group 1: Business Overview - Sichuan Shuangma operates in two main sectors: cement building materials and biopharmaceuticals [1]. - The company has two cement production lines with an annual capacity of 2 million tons and two aggregate production lines with an annual capacity of 5 million tons [1]. - In the biopharmaceutical sector, the company, through its subsidiary Hubei Jianxiang, is involved in the raw material pharmaceutical business [1]. Group 2: Recent Developments - Hubei Jianxiang Biopharmaceutical Co., Ltd., a subsidiary of Sichuan Shuangma, recently received the "Export EU Raw Material Drug Certification Document" from the Hubei Provincial Drug Administration, and its liraglutide production line passed the GMP compliance inspection [1]. - This certification is expected to help the company expand into international markets and enhance product competitiveness [1]. - The company has stated that it has not yet participated in the Yarlung Tsangpo River hydropower project [1]. Group 3: Market Activity - On July 30, the main funds for Sichuan Shuangma saw a net outflow of 18.2757 million yuan [2].

Core Viewpoint - Sichuan Shuangma announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. received compliance certificates from the Hubei Provincial Drug Administration, confirming that its production line for the active pharmaceutical ingredient Liraglutide meets GMP standards equivalent to those of the EU and WHO [1] Group 1 - Hubei Jianxiang received the "GMP Compliance Inspection Notification" and "Written Confirmation for Active Substances Exported to EU" from the Hubei Provincial Drug Administration [1] - The A101 production line for Liraglutide at Hubei Jianxiang was inspected and found to comply with China's GMP requirements [1] - The GMP standards met by Hubei Jianxiang are equivalent to those set by the EU, WHO, and ICH Q7 guidelines [1]

（编辑 袁冠琳） 证券日报网讯 四川双马7月30日在互动平台回答投资者提问时表示，未来公司将持续推动核心业务的深 入发展，聚焦于空间大、成长性好、盈利能力良好的生物科技等领域，延伸寻找有协同效应的业务，确 保长期的可持续发展和增长，为股东创造持续的股东回报。若涉及相关情况，公司将根据相关法律法规 及时履行信息披露义务。 ...

证券代码：000935 证券简称：四川双马 公告编号：2025-35 四川和谐双马股份有限公司（以下简称"公司"）控股子公司湖北健翔生物 制药有限公司（以下简称"湖北健翔"）于近期收到了湖北省药品监督管理局出 具的《湖北省药品 GMP 符合性检查告知书》（编号：鄂 GMP 2025-95 号）和《出 口欧盟原料药证明文件》（Written confirmation for active substances exported to EU， 以下简称"WC 证书"）（编号：HB250024）。湖北健翔 A101 车间 A101 生产 线（原料药利拉鲁肽）经湖北省药品监督管理局现场检查，符合中国药品 GMP （即，药品生产质量管理规范）的要求，等同于欧盟、世界卫生组织以及 ICH Q7 （即，国际人用药品注册技术协调会关于原料药的药品生产质量管理规范指南） 药品 GMP 要求。 一、本次通过药品 GMP 检查及获得出口欧盟原料药证明文件（WC 证书） 的具体情况 （一）《湖北省药品 GMP 符合性检查告知书》（编号：鄂 GMP 2025-95 号） 5、检查结论：符合要求 （二）《出口欧盟原料药证明文件》（WC ...

Core Viewpoint - Sichuan Shuangma's subsidiary, Hubei Jianxiang Biopharmaceutical Co., Ltd., has received compliance certificates from the Hubei Provincial Drug Administration, indicating that its production line meets GMP standards equivalent to those of the EU and WHO [1] Group 1 - Hubei Jianxiang has obtained the "Notice of Compliance Inspection for Drug GMP" and "Certificate of Export of Raw Materials to the EU" from the Hubei Provincial Drug Administration [1] - The A101 production line for the raw material drug Liraglutide has passed the on-site inspection and complies with China's GMP requirements [1] - The GMP compliance is recognized as equivalent to the standards set by the EU, WHO, and ICH Q7 guidelines for raw material drug production [1]